6IRA Stock Chart & Stats
€0.18
-€0.01(-1.25%)
At close: 4:00 PM EST
€0.18
-€0.01(-1.25%)
Day’s Range― - ―
52-Week Range€0.10 - €0.27
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€22.77M
Enterprise Value€95.31
Total Cash (Recent Filing)€34.22M
Total Debt (Recent Filing)€24.20M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding148,632,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)4.30
Price to Sales (P/S)2.30
P/FCF Ratio-2.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)€9.23M
Bulls Say, Bears Say
Bulls Say
Improved Balance-sheet ResilienceLower leverage and roughly 97M of equity provide a stronger financial cushion than in prior years. This reduces balance-sheet risk and may give IRLAB more flexibility to fund development while it remains pre-commercial.
Losses Have Narrowed SubstantiallyThe improvement in losses suggests cost control and/or a better revenue mix may be developing. Although IRLAB remains unprofitable, continued progress could extend its funding runway and improve the economics of its clinical-stage programs.
Specialized CNS Drug-development FocusA focused CNS strategy gives IRLAB domain specialization in a significant area of unmet medical need. Clinical-stage candidates and a concentrated research platform can support future partnering or milestone opportunities if development succeeds.
Bears Say
Persistent Operating Cash BurnSustained negative operating and free cash flow means the business is not yet self-funding. Continued cash consumption can require additional financing, constrain development priorities, and increase dilution or funding risk before commercial revenue emerges.
Deep Losses And Contracting RevenueSevere losses and a shrinking top line indicate that current revenue is insufficient to cover the cost base. Unless clinical progress translates into partnerships or products, weak operating leverage may persist and continue eroding shareholder capital.
Reliance On External FinancingDependence on equity or other external funding leaves IRLAB exposed to financing availability and potential shareholder dilution. This is a structural risk for a pre-commercial biotech until collaboration income or product sales become dependable.
IRLAB Therapeutics AB Class A News
6IRA FAQ
What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
IRLAB Therapeutics AB Class A lowest stock price was €0.10 and its highest was €0.27 in the past 12 months.
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is €22.77M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
IRLAB Therapeutics AB Class A’s upcoming earnings report date is Nov 13, 2026 which is in 49 days.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
IRLAB Therapeutics AB Class A released its earnings results on Aug 26, 2026. The company reported -€0.02 earnings per share for the quarter.
Is IRLAB Therapeutics AB Class A overvalued?
According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 148,632,140 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
IRLAB Therapeutics AB Class A reported an EPS of -€0.02 in its last earnings report. Following the earnings report the stock price went up 1.316%.
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in DE:6IRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat, which is undergoing phase IIb clinical trials for the management of postural dysfunction. In the preclinical phase, IRLAB is advancing research programs like IRL942 and 1009, aimed at neurodegenerative conditions and the aging process, as well as IRL757, designed to alleviate apathy in various neurological disorders. Additionally, the company is conducting a research project, P003, focused on creating new therapies for individuals with a recent Parkinson's disease diagnosis. IRLAB Therapeutics AB (publ) was founded in 2013 and has its headquarters in Gothenburg, Sweden.
Technical Analysis
Alzinova AB
―
AlzeCure Pharma AB
―
BioArctic AB Class B
―
SynAct Pharma AB
―
Saniona AB
―